Driven by self-medication trends, health-conscious consumers, and innovative formulations, the OTC drugs market thrives on the widespread availabilit ...

She pointed to several other trials of methotrexate in both hand and knee OA that showed little to no benefit, and that in ...

The recent run of successful equity block trades continued on Wednesday evening, with trades in cement maker Heidelberg ...

Pfizer PFE has sold off its remaining stake in consumer health company Haleon HLN to institutional investors and Haleon itself for around $3.3 billion. Pfizer sold its 7.3% stake in Haleon ...

Under the deal, Sensodyne maker Haleon has agreed to buy back 44 million shares from Pfizer, currently its largest shareholder, with 618 million shares being sold to institutional investors. The total ...

Pfizer (NYSE:PFE) has generated £2.5B ($3.24B) after selling its entire stake in Haleon (NYSE:HLN), the consumer healthcare company it established with the British pharmaceutical giant GSK (GSK ...

Pfizer sold its remaining 7.3% stake in Haleon for $3.1 billion, fully exiting its position in the company. Haleon expects 2025 organic revenue growth of 4% to 6%, with stronger performance in the ...

With Pfizer’s final stake sale in the bag, the two Big Pharma companies behind Haleon’s genesis have formally parted ways with the standalone consumer health giant. After charting similar ...

Drugmaker Pfizer has sold its entire stake in Haleon for about £2.5 billion to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for the deal said today.

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Pfizer has completing its full exit from Weybridge-headquartered health firm Haleon. Haleon has agreed to an off-market purchase of 44,155,844 ordinary shares of £0.01 each from Pfizer. The off-market ...